QR Pharma Begins Collaboration on Posiphen and Huntington's disease

QR Pharma, Inc. announced today a new collaborative research agreement with The Rockefeller University aimed at developing a treatment for Huntington's disease . The collaboration will focus on preclinical research involving QR's lead drug candidate, Posiphen A .

http://ift.tt/1F6qEKQ